NovoCure Limited announced on March 26, 2026, that it has achieved positive results from its Phase 2 PANOVA-4 clinical trial, which evaluated the efficacy of Tumor Treating Fields (TTFields) therapy in combination with atezolizumab (Tecentriq®), gemcitabine, and nab-paclitaxel as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial met its pre-specified primary endpoint, demonstrating a statistically significant improvement in disease control rate (DCR). Specifically, the DCR for patients receiving the combination therapy was 74.4%, compared to 48% in the historical control group receiving gem/nab-paclitaxel alone. This represents a difference of 26.4% with a one-sided p-value of less than 0.001, indicating strong statistical significance. The results suggest that TTFields therapy may enhance treatment outcomes for patients with this aggressive form of cancer. The trial included 78 patients treated with the combination therapy, and the company plans to present additional results at future scientific forums. The positive findings are expected to bolster NovoCure's position in the oncology market, particularly in the treatment of pancreatic cancer, which has a notoriously low survival rate. The company is committed to advancing TTFields therapy as a viable treatment option and is grateful to the patients and investigators involved in the trial.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.